

ROFEL SHRI G.M. BILAKHIA COLLEGE OF PHARMACY

APPROVED BY PHARMACY COUNCIL OF INDIA (PCI) AND AFFILIATED TO GUJARAT TECHNOLOGICAL UNIVERSITY, AHMEDABAD

Managed by Rotary Foundation for Education and Learning (ROFEL) Trust

Estd. In 1999

ROFEL NAMDHA CAMPUS, Vapi-Namdha Road, P.B. No. 11, Vapi (West) - 396191, Dist.- Valsad (Gujarat) Tel: 9727723722 |42 | 62; Email: rofelpharm@gmail.com; website: www.rofelpharmacy.ac.in

REPORT OF GUEST/EXTENSION LECTURE

Title of Guest Lecture (Webinar): Vaccine Safety Surveillance

Speaker: Dr. Shivani Desai, Assistant Professor, Dr. D. Y. Patil Institute of Pharmaceutical

Education and Research, Pune

Date & Venue: 19th March, 2022 on virtual platform through Google meet

Summary Report:

Dr. Shivani Desai shared vital information on Vaccine safety surveillance- a key aspect in current pandemic. Dr. Desai explained that successful immunisation programmes require high-quality vaccines and safe immunisation techniques. During the pre-licensure stage, all vaccines are subjected to extensive safety testing. In India, the Adverse Events Following Immunization (AEFI) Surveillance programme is an important aspect of the routine immunisation programme for evaluating vaccine safety following licensure phase. Dr Desai also shared information regarding the national vaccination programme unveils newly developed vaccines for various age groups and coverage improves, concerns regarding vaccine hesitancy and confidence are likely to arise more frequently, and the AEFI surveillance programme will be tasked with responding to community concerns and maintaining public confidence in vaccines. Dr. Desai also explained role of Active and Passive surveillance in Vaccine safety evaluation. Along with ensuring equitable access to vaccines for all people around the world, countries must make immediate preparations for COVID-19 vaccine safety surveillance. To evaluate if the vaccine's benefit-risk profile has changed, safety surveillance must be capable of evaluating adverse events of special interest (AESI) and adverse events following immunisation, as well as anticipating coincidental events that could be related to the vaccine.





(Dr. Shivani Desai delivered a session on Vaccine Safety Surveillance-2022)